- Home
- BWIN vs LIVN Comparison
BWIN vs LIVN Comparison
Compare BWIN & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWIN
- LIVN
- Stock Information
- Founded
- BWIN 2011
- LIVN 1987
- Country
- BWIN United States
- LIVN United Kingdom
- Employees
- BWIN N/A
- LIVN N/A
- Industry
- BWIN Specialty Insurers
- LIVN Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- BWIN Finance
- LIVN Health Care
- Exchange
- BWIN Nasdaq
- LIVN Nasdaq
- Market Cap
- BWIN 3.1B
- LIVN 2.8B
- IPO Year
- BWIN 2019
- LIVN 1993
- Fundamental
- Price
- BWIN $41.23
- LIVN $48.30
- Analyst Decision
- BWIN Buy
- LIVN Buy
- Analyst Count
- BWIN 6
- LIVN 7
- Target Price
- BWIN $44.80
- LIVN $67.14
- AVG Volume (30 Days)
- BWIN 536.9K
- LIVN 483.1K
- Earning Date
- BWIN 02-25-2025
- LIVN 02-19-2025
- Dividend Yield
- BWIN N/A
- LIVN N/A
- EPS Growth
- BWIN N/A
- LIVN 759.09
- EPS
- BWIN N/A
- LIVN 0.43
- Revenue
- BWIN $1,343,793,000.00
- LIVN $1,241,739,000.00
- Revenue This Year
- BWIN $15.96
- LIVN $10.10
- Revenue Next Year
- BWIN $13.09
- LIVN $5.43
- P/E Ratio
- BWIN N/A
- LIVN $112.77
- Revenue Growth
- BWIN 13.89
- LIVN 11.04
- 52 Week Low
- BWIN $21.70
- LIVN $43.15
- 52 Week High
- BWIN $55.82
- LIVN $64.48
- Technical
- Relative Strength Index (RSI)
- BWIN 55.23
- LIVN 50.54
- Support Level
- BWIN $34.78
- LIVN $47.23
- Resistance Level
- BWIN $38.70
- LIVN $48.73
- Average True Range (ATR)
- BWIN 1.35
- LIVN 1.13
- MACD
- BWIN 0.69
- LIVN 0.29
- Stochastic Oscillator
- BWIN 92.81
- LIVN 85.90
About BWIN The Baldwin Insurance Group Inc. Class A Common Stock
The Baldwin Insurance Group Inc is a United States-based insurance distribution firm. Its products include Business Insurance, Benefits Consulting, Reinsurance, Specialty MGA, Embedded Insurance., Personal insurance, etc.
About LIVN LivaNova PLC
UK-based LivaNova was born of a combination between Cyberonics in the us and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the us market, another 21% from Europe, and the remainder from the rest of the world.